Brief: Lineage Cell Therapeutics Says Intends To Meet With FDA On Clinical Development Plan For Opregen
20/07/2021 13:33
July 20 (Reuters) - Lineage Cell Therapeutics Inc LCTX.A :
* OPREGEN® CLINICAL DATA CONTINUES TO DEMONSTRATE FUNCTIONAL
AND
ANATOMICAL IMPROVEMENTS IN PATIENTS WITH DRY AMD WITH GEOGRAPHIC
ATROPHY
* LINEAGE CELL THERAPEUTICS INC - COMPANY INTENDS TO MEET
WITH FDA
IN Q4 2021 TO DISCUSS CLINICAL DEVELOPMENT PLAN FOR OPREGEN
Source text for Eikon: ID:nBwfYWYta
Further company coverage: LCTX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million